N-甲基-N-(3-吡啶基甲基)-乙酰胺 | 69966-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-甲基-N-(3-吡啶基甲基)-乙酰胺
• 英文名称: N-methyl-N-(pyridin-3-ylmethyl)acetamide
• 英文别名: 3-(N-Methylacetamidomethyl)-pyridin；3--pyridin
• CAS: 69966-50-3
• 化学式: C₉H₁₂N₂O
• mdl: MFCD00052323
• 分子量: 164.207
• InChiKey: UVUKRYCSGXKFEL-UHFFFAOYSA-N

物化性质

• 沸点：
  122 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-甲基-N-(3-吡啶基甲基)-乙酰胺 在 N-羟基邻苯二甲酰亚胺 、 氧气 、 2,4,6-三甲基吡啶高氯酸盐 作用下， 以 丙酮 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 以59%的产率得到N-acetyl-N-methylnicotinamide
  参考文献：
  名称：

  NHPI-Mediated Electrochemical α-Oxygenation of Amides to Benzimides

  摘要：

  DOI：

  10.1021/acs.joc.2c02700
• 作为产物：
  描述：

  N-甲基-N-(3-甲基吡啶)胺 、 乙酸酐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以92%的产率得到N-甲基-N-(3-吡啶基甲基)-乙酰胺
  参考文献：
  名称：

  NHPI-Mediated Electrochemical α-Oxygenation of Amides to Benzimides

  摘要：

  DOI：

  10.1021/acs.joc.2c02700

文献信息

• Dihydrothienopyrimidines for the Treatment of Inflammatory Diseases
  申请人：Pouzet Pascale

  公开号：US20080096882A1

  公开（公告）日：2008-04-24

  The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  该发明涉及公式1的新二氢噻吡嘧啶，以及其药理学上可接受的盐、对映体、旋光异构体、消旋体、水合物或溶剂合物，其中X为SO或SO2，但最好为SO，R1、R2和R3在描述中给出的含义，并且适用于治疗呼吸道或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症，以及含有这些化合物的药物组合物。
• Hsp90 FAMILY PROTEIN INHIBITORS
  申请人：Nara Shinji

  公开号：US20090247522A1

  公开（公告）日：2009-10-01

  The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

  本发明提供了Hsp90家族蛋白抑制剂，其包含作为活性成分的苯甲酰化合物，其通式表示为（I）：（其中n表示0到10的整数；R1表示取代或未取代的低烷氧基，取代或未取代的低烷氧羰基，CONR7R8或类似物；R2表示取代或未取代的芳基，取代或未取代的芳香杂环基或类似物；R3和R5，可以相同也可以不同，分别表示氢原子，取代或未取代的低烷基，取代或未取代的低烯基或类似物；R4和R6，可以相同也可以不同，分别表示氢原子，卤素，取代或未取代的低烷基，取代或未取代的芳基或类似物）或其前药，或其药学上可接受的盐。
• Hsp90 family protein inhibitors
  申请人：Nara Shinji

  公开号：US20070032532A1

  公开（公告）日：2007-02-08

  The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

  本发明提供了Hsp90家族蛋白抑制剂，其作为活性成分包括由通式（I）表示的苯甲酰化合物： （其中，n代表0至10的整数；R1代表取代或未取代的较低烷氧基、取代或未取代的较低烷氧羰基、CONR7R8等；R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基等；R3和R5，可以相同也可以不同，每个代表氢原子、取代或未取代的较低烷基、取代或未取代的较低烯基等；R4和R6，可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基、取代或未取代的芳基等）或其前药，或所述苯甲酰化合物或其前药的药学上可接受的盐。
• PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN
  申请人：Frutos Rogelio

  公开号：US20100222585A1

  公开（公告）日：2010-09-02

  The invention relates to improved methods of preparing dihydrothienopyrimidines of formula 1, and intermediates thereof, (I) wherein X is SO or SO 2 , preferably SO, and wherein R A , R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the description. The methods according to this invention are more suitable for large-scale synthesis of said pounds than prior methods because the new synthetic process avoids distillation and chromatographic purification between steps and results in a higher overall yield of the desired product.

  本发明涉及改进的制备式1的二氢噻唑嘧啶化合物及其中间体的方法，其中X为SO或SO2，优选为SO，RA、R1、R2、R3、R4和R5具有所述描述中给出的含义。本发明的方法比先前的方法更适用于大规模合成所述化合物，因为新的合成过程避免了蒸馏和色谱纯化步骤，从而得到所需产物的总收率更高。
• PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF
  申请人：Ebiike Hirosato

  公开号：US20100324284A1

  公开（公告）日：2010-12-23

  A preventive or therapeutic agent of a proliferative disease such as cancer, having superior PI3K inhibitory effects, superior cell proliferation inhibitory action as well as superior stability in a body and water solubility, is provided. A compound represented by formula (I): [wherein, Q represents a linking group represented by —X—Y—; X represents a single bond —CO—, —CONH—, —CON(C 1-4 alkyl)-, —CS—, —CSNH—, —CSN(C 1-4 alkyl)-, or —SO 2 —; Y represents a single bond, arylene or heteroarylene; provided that X and Y are not simultaneously single bonds; and R 1 represents —C 0-6 alkylene-(A) m -C 1-6 alkyl, or C 0-6 alkylene-(A) m -C 0-6 alkylene-(heterocycle)] or a pharmaceutically acceptable salt thereof.

  提供了一种预防或治疗增殖性疾病（如癌症）的药物，具有优越的PI3K抑制作用、优越的细胞增殖抑制作用以及在体内具有优越的稳定性和水溶性。该化合物的式子为（I）：[其中，Q表示由—X—Y—表示的连接基；X表示单键—CO—、—CONH—、—CON（C1-4烷基）-、—CS—、—CSNH—、—CSN（C1-4烷基）-或—SO2—；Y表示单键、芳基或杂芳基；但X和Y不能同时为单键；R1表示—C0-6烷基-(A)m-C1-6烷基，或C0-6烷基-(A)m-C0-6烷基-(杂环)]或其药学上可接受的盐。